CIK 0000906709 · Non-accelerated filer<br>Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943134940
- Phone
- 4154825300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $43,476
- in 2 filings
Net −$43,476. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-30 | CHESS ROBERT Director | Grant or award · Stock Option | +8,000 | 8,000 | ||
| 2025-09-30 | Brainard Diana Director | Grant or award · Stock Option | +8,000 | 8,000 | ||
| 2025-09-30 | Ajer Jeffrey Robert Director | Grant or award · Stock Option | +8,000 | 8,000 | ||
| 2025-09-09 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −2,100 | $45.16 | $95K | 53,908 |
| 2025-09-09 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −1,200 | $46.41 | $56K | 52,708 |
| 2025-09-09 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −2,156 | $47.49 | $102K | 50,552 |
| 2025-09-09 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −1,210 | $48.18 | $58K | 49,342 |
| 2025-09-05 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −3,304 | $37.87 | $125K | 59,370 |
| 2025-09-05 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −2,226 | $38.82 | $86K | 57,144 |
| 2025-09-05 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −1,136 | $39.89 | $45K | 56,008 |
| 2025-09-04 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −793 | $32.43 | $26K | 18,390 |
| 2025-09-04 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −432 | $33.60 | $15K | 17,958 |
| 2025-09-04 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −189 | $34.41 | $7K | 17,769 |
| 2025-09-04 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −307 | $35.69 | $11K | 17,462 |
| 2025-09-04 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −1,923 | $32.37 | $62K | 65,917 |
| 2025-09-04 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −1,496 | $33.54 | $50K | 64,421 |
| 2025-09-04 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −613 | $34.40 | $21K | 63,808 |
| 2025-09-04 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −1,134 | $35.80 | $41K | 62,674 |
| 2025-09-02 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −485 | $30.10 | $15K | 19,183 |
| 2025-09-02 | ROBIN HOWARD W President & CEO | Sale 10b5-1 | −1,500 | $30.16 | $45K | 67,840 |
Page 3 of 18 · 355 trades